X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 -
Covered in this story
Call it yourself
No calls on $XFOR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on X4 Pharmaceuticals →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.